Cargando…

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Detalles Bibliográficos
Autores principales:	Zhang, Tao, Qu, Rong, Chan, Shingpan, Lai, Mengzhen, Tong, Linjiang, Feng, Fang, Chen, Hongyu, Song, Tingting, Song, Peiran, Bai, Gang, Liu, Yingqiang, Wang, Yanan, Li, Yan, Su, Yi, Shen, Yanyan, Sun, Yiming, Chen, Yi, Geng, Meiyu, Ding, Ke, Ding, Jian, Xie, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439646/ https://www.ncbi.nlm.nih.gov/pubmed/37598189 http://dx.doi.org/10.1186/s12943-023-01842-7

Ejemplares similares

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2020)

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2021)

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo
por: Lai, Mengzhen, et al.
Publicado: (2023)

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK
por: Song, Peiran, et al.
Publicado: (2022)

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
por: Liu, Yingqiang, et al.
Publicado: (2021)

Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
por: Xu, Wanhong, et al.
Publicado: (2018)

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
por: Liu, Yingqiang, et al.
Publicado: (2023)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
por: Jiang, Kaili, et al.
Publicado: (2021)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
por: Mancini, Maicol, et al.
Publicado: (2017)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo
por: Wang, Jie, et al.
Publicado: (2022)

Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review)
por: Wang, Qian, et al.
Publicado: (2023)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014)

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
por: Zhou, Yuanfeng, et al.
Publicado: (2012)

The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo
por: Ma, Jingui, et al.
Publicado: (2008)

Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors
por: Zhao, Wen, et al.
Publicado: (2021)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
por: Zhang, Zhang, et al.
Publicado: (2018)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Function of Dental Follicle Progenitor/Stem Cells and Their Potential in Regenerative Medicine: From Mechanisms to Applications
por: Bi, Ruiye, et al.
Publicado: (2021)

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo
por: Xie, Hua, et al.
Publicado: (2011)

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2018)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
por: Han, Luwei, et al.
Publicado: (2021)

Third generation EGFR TKIs: current data and future directions
por: Tan, Chee-Seng, et al.
Publicado: (2018)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan, Yong-hong, et al.
Publicado: (2018)

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Hsu, Chia-Chi, et al.
Publicado: (2021)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
por: Kwon, Yoojung, et al.
Publicado: (2019)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation
por: Zhang, Jie, et al.
Publicado: (2015)

Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation
por: Zhang, Jie, et al.
Publicado: (2020)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
por: Ye, Hua, et al.
Publicado: (2020)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u45j8t1etv69s3p8th475kntep